Investors underwhelmed by Phase III Adcetris results

27 June 2017

Takeda Pharmaceutical (TSE: 4502) and Seattle Genetics (Nasdaq: SGEN) say their ECHELON-1 Phase III trial of Adcetris (brentuximab vedotin) has met its primary endpoint.

The drug, an antibody-drug conjugate (ADC), is being investigated in combination with chemotherapy as a frontline therapy for Hodgkin lymphoma, where it is not currently approved.

While the data showed the combination bettered progression-free survival rates in the control arm by 5%, shareholders appeared to deem this too modest an improvement, with Seattle’s share price falling a tenth.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK